Locust Walk has been active in Asia, in particular, Japan for nearly half of the firm’s history and we are deeply rooted in the market. We have advised on more than a dozen transactions during our history in Japan and have successfully helped deal making between US/EU companies and Japan pharma.

However, being in contact with Japanese BD executives on a day-to-day basis, we felt they had more of a story to tell which was not fully appreciated by companies outside of Japan.

In order to bridge that gap in perception and bring the global biopharma community closer to the Japanese pharma industry, we are pleased to present the Deal Makers of Japan-Exclusive Interview Series with Japan’s best dealmakers. The Locust Walk Japan team sat down with the following companies in this inaugural series: ASKA Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Otsuka Pharmaceutical Co., Ltd., SymBio Pharmaceuticals Limited.